The new agreement grants Ideactifs distribution rights for Bimuno GOS as a B2B ingredient in the French and Belgian markets. This collaboration will support the expanding presence of Bimuno GOS in Europe and leverage the growing popularity of prebiotic products among health consumers.
As the most studied commercially available galactooligosaccharide, Bimuno GOS' safety and efficacy are supported by over 110 scientific publications, including more than 20 clinical trials, making it the most comprehensively studied prebiotic of its kind.
The scientific backing underscores its influence on various aspects of gastrointestinal, digestive, immune, and cognitive health.
Dr. Frederic Narbel, VP of B2B Sales at Clasado, expressed enthusiasm about the new partnership: "We are delighted to team up with Ideactifs to expand our reach to customers in France and Belgium. Alongside rising gut health awareness, demand for prebiotics continues to increase among consumers.
"As such, this collaboration presents an exciting opportunity to showcase the exceptional benefits of Bimuno GOS. Operating very successfully across the French and Belgian nutraceutical markets, the Ideactifs team has a wealth of technical expertise, which will help their customers to get the most from Bimuno GOS.”
Bruno Le Mer, Director at Ideactifs, added: "We are thrilled to bring Bimuno GOS to formulators across France and Belgium, adding to our comprehensive portfolio of functional ingredients. Gut health awareness is on the rise globally, and consumers are increasingly focusing on nurturing the gut microbiome and the beneficial bacteria that reside there.
“Bimuno GOS, with its proven nourishment of good bacteria, offers remarkable benefits for formulators, backed by one of the most comprehensive scientific portfolios on the market. It’s exciting to be working with a prebiotic that demonstrates efficacy starting from just 1.37g per day, making it an ideal ingredient for a diverse range of product applications. We look forward to helping formulators across France and Belgium to enhance product development with one of the most trusted prebiotics."
According to research firm Mordor Intelligence, the European prebiotics market is projected to experience a robust compound annual growth rate of over 7%, powered by growing consumer demand.
Bimuno GOS background
Recent data published in the European Journal of Sport Science indicated that daily supplementation with 2.9 grams per of Clasado’s Bimuno GOS experienced a two-day reduction the duration of symptoms of upper respiratory infection.
Secretion of salivary immunoglobulin A (sIgA), the main immune factor in saliva and known to be the first line of defence in protecting against infection, was also increased by 42% in elite rugby players receiving the prebiotic after 168 days of supplementation.
The scientists from Nottingham Trent University, the University of Reading, and London Irish Rugby Football Club., said in their report: “To our knowledge, this is the first study to assess the effect of a prebiotic dietary intervention on URS [upper respiratory symptoms] and GIS [gastrointestinal symptoms] in an elite-athletic population.
“The 2-day reduction in URS episode duration is relevant for athletes and coaches, potentially aiding a quicker return to play following a URS episode.”
Just last Spring, the European Food Safety Authority (EFSA) gave the thumbs up to extending the use of Bimuno’s galactooligosaccharises (GOS) as a novel food for use in special medical purposes (FSMP).
The opinion by the food authority paved the way for Bimuno GOS to be used for the dietary management of impaired gastrointestinal issues in hospitalised patients.
Ideactifs
Based in Paris, Ideactifs distributes healthy ingredients targeting a range of health parameters to food professionals in France and Benelux.
Ingredients in the firm's portfolio include trademarked collagens such as Fortigel, Verisol, and Tendoforte, vitamins such as K2VITAL, from Kappa Bioscience, a range of plant extracts including Dracobelle Nude, EnduBerry Nu, FenuKale Nu, and more.